View:
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* NABI ------------------------------------------ (Name of Issuer) Common Stock, par value $ .10 per share ------------------------------------------ (Title of Class of Securities) 628716102 ------------------------------------------ (CUSIP Number) Jose M. de Lasa, 100 Abbott Park Road Abbott Park, Illinois 60064-6049; Phone 847 937 8905 ------------------------------------------------------ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) June 2, 2000 ------------------------------------------ (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_]. NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies should be sent. * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 628716102 - ------------------------------------------------------------------------------- 1) NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Abbott Laboratories IRS Identification No. 36-0698440 - ------------------------------------------------------------------------------- 2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] - ------------------------------------------------------------------------------- 3) SEC USE ONLY - ------------------------------------------------------------------------------- 4) SOURCE OF FUNDS Not Applicable - ------------------------------------------------------------------------------- 5) CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [ ] - ------------------------------------------------------------------------------- 6) CITIZENSHIP OR PLACE OF ORGANIZATION Illinois - ------------------------------------------------------------------------------- NUMBER OF (7) SOLE VOTING POWER SHARES 1,630,000 BENEFICIALLY (8) SHARED VOTING POWER OWNED BY 0 EACH (9) SOLE DISPOSITIVE POWER REPORTING 1,630,000 PERSON WITH (10) SHARED DISPOSITIVE POWER 0 - ------------------------------------------------------------------------------- 11) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,630,000 - ------------------------------------------------------------------------------- 12) CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) [ ] - ------------------------------------------------------------------------------- 13) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 4.56% (see Item 5 below) - ------------------------------------------------------------------------------- 14) TYPE OF REPORTING PERSON (SEE INSTRUCTIONS) CO - ------------------------------------------------------------------------------- Page 2 of 4 pages The following information amends and supplements the original Schedule 13D filed by Abbott Laboratories ("Abbott") on October 19, 1992. ITEM 1. SECURITY AND ISSUER This statement relates to shares of the common stock, par value $ .10 per share (the "Common Stock"), of NABI, a Delaware corporation (the "Issuer"), whose principal executive offices are located at 5800 Park of Commerce Boulevard N.W., Boca Raton, Florida 33487. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER (a) As of June 6, 2000, Abbott Laboratories ("Abbott") was the beneficial owner of 1,630,000 shares of Common Stock (the "Shares"), representing approximately 4.56% of the outstanding shares of the Common Stock. The calculation of the foregoing percentage is based on the number of shares of Common Stock shown as being outstanding on the Form 10-Q Quarterly Report filed by the Issuer with the Securities and Exchange Commission for the quarterly period ended April 1, 2000. (b) Abbott has sole power to vote or to direct the vote and the sole power to dispose or to direct the disposition of the Shares. (c) In the past 60 days, Abbott has effected the following open market sales of the Common Stock: Page 3 of 4 pages
Date Number of Shares Sold Average Price Per Share - ---- --------------------- ----------------------- May 17, 2000 10,000 $5.6406 May 18, 2000 10,000 $5.5000 May 19, 2000 25,000 $5.1750 May 22, 2000 10,000 $5.2500 May 23, 2000 20,000 $5.4375 May 24, 2000 20,000 $5.0000 May 25, 2000 5,000 $5.3125 May 26, 2000 15,000 $5.0000 May 30, 2000 40,000 $5.0781 May 31, 2000 35,000 $5.5000 June 1, 2000 10,000 $5.8125 June 2, 2000 40,000 $5.5781 June 5, 2000 30,000 $5.3542 June 6, 2000 100,000 $5.5313 (e) On June 2, 2000, Abbott ceased to be the beneficial owner of more than five percent of the Common Stock. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Abbott Laboratories DATED: June 12, 2000 By: /s/ Gary P. Coughlan -------------------------------------- Gary P. Coughlan, Senior Vice President, Finance and Chief Financial Officer Page 4 of 4 pages